INTRODUCTION
DNA methylation is an epigenetic process that influences cell fate. While aberrant DNA methylation is observed in many types of malignancies (You and Jones, 2012) , a causative role for such changes has been difficult to identify. Recently, mutations in the de novo DNA methyltransferase (DNMT) 3A have been found in a variety of hematologic malignancies, suggesting a central role for this epigenetic regulator in preventing disease development (Reviewed in (Yang et al., 2015) . Approximately 25% of patients who have myeloid or lymphoid malignancies, including acute myeloid leukemia (AML) (Ley et al., 2010) and T-cell acute lymphoblastic leukemia (T-ALL) Roller et al., 2013; Van Vlierberghe et al., 2013) harbor DNMT3A mutations. In AML, a hotspot mutation at Arginine 882 (R882) is most prevalent, occurring in about 60% of DNMT3A mut patients (Ley et al., 2010) . This alteration is thought to act as a dominant-negative, depleting most of the DNMT3A activity in the cell except for about 20% of wild-type activity (Kim et al., 2013; Russler-Germain et al., 2014) . In T-ALL, the R882 mutation is less prevalent, and about 62% of DNMT3A mut patients harbor homozygous or compound heterozygous (biallelic) mutations . Together, these findings indicate that DNMT3A acts as a classic tumor suppressor, with a loss of most, or all, of its function promoting malignancy development..
Dnmt3a is highly expressed in hematopoietic stem cells (HSCs), where its loss promotes
HSC self-renewal at the expense of efficient differentiation (Challen et al., 2012) . In AML patients, DNMT3A mutations can be found in non-leukemic and leukemic cells in the peripheral blood (Corces-Zimmerman et al., 2014; Shlush et al., 2014) . Moreover, blood cells with DNMT3A mutations can be found in healthy individuals, particularly with age (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014) . DNMT3A mutations in humans are associated with increased risk of leukemia, but alone are insufficient for transformation. The presence of DNMT3A mutations in HSCs that can behave relatively normally, and the latency of disease development in individuals that harbor DNMT3A mut HSCs, suggests that secondary mutations are key in driving the particular type of disease development.
Previous work with mice transplanted with Dnmt3a knock-out (KO) cells is consistent with the view that mutations in DNMT3A alone are insufficient for disease. Mice transplanted with Dnmt3a KO HSCs developed a variety of hematologic malignances, such as T-ALL, B-ALL, myelodysplastic syndrome (MDS), AML, and CMML with a long latency (3 to 14 months) (Celik et al., 2014; Mayle et al., 2014) . Here we sought to combine Dnmt3a ablation with a specific additional mutation to investigate the mechanisms through which loss of DNMT3A promotes leukemia development. Because DNMT3A mutations are found in both lymphoid and myeloid leukemia, we introduced a secondary mutation that co-occurs with DNMT3A mut in both lineages.
In AML, 30% of patients with DNMT3A mutations harbor internal tandem duplications (ITD) in the fms-like tyrosine kinase 3 (FLT3-ITD) (Ley et al., 2010) . DNMT3A and FLT3-ITD mutations both commonly occur in early immature T-ALL (Van Vlierberghe et al., 2013) . We therefore reasoned that FLT3-ITD expression in Dnmt3a-KO mice could be used to study the role of DNMT3A in both lymphoid and myeloid malignancies.
RESULTS

Dnmt3a loss accelerates FLT3-ITD lymphoid leukemia
We sought to establish a model with both DNMT3A loss and FLT3-ITD expression. Because expression of FLT3-ITD via retrovirus can generate murine T-ALL (Kelly et al., 2002) , we first used this strategy in Dnmt3a-KO cells. We deleted Dnmt3a in 8-week-old Mx1-Cre + ;Dnmt3a fl/fl mice, using polyinosinic-polycytidylic acid (pIpC) to generate animals with Dnmt3a -/-bone marrow. From these mice, we transduced 5-fluorouracil-stimulated hematopoietic stem and progenitor cells with an MSCV retrovirus containing FLT3-ITD-IRES-GFP (3aKO/FLT3-ITD) or IRES-GFP alone (3aKO) and transplanted the cells into lethally irradiated recipients. A separate group of mice, Mx1-Cre + ;Dnmt3a +/+ were also transduced with FLT3-ITD-IRES-GFP (FLT3-ITD), and IRES-GFP alone (WT) ( Figure 1A ). All mice received pIpC injections to control for possible interferon-mediated effects (Baldridge et al., 2010) .
Mice transplanted with FLT3-ITD or 3aKO/FLT3-ITD bone marrow cells developed leukemia. Strikingly, 3aKO/FLT3-ITD mice had significantly shorter survival times (79 days vs.
116 days) than did FLT3-ITD mice ( Figure 1B ). Both groups showed weight loss, splenomegaly, and thymomegaly ( Figures 1C and 1D ) with widespread GFP+ cell infiltration in the bone marrow ( Figure 1E ). Notably, the 3aKO/FLT3-ITD group had larger spleens and smaller thymuses (Figures 1C and 1D) . Immunophenotyping revealed GFP+ populations of T-cells that expressed surface markers found on immature thymocytes and progenitor cells (CD4+CD8+CD25+; Figures 1E and S1A). At this time point, mice transplanted with cells from the 3aKO-alone showed no overt phenotype (Figure 1 , S1). Histological examination revealed extensive infiltration of peripheral blood, bone marrow, and spleen ( Figure 1F ) and nonhematopoietic organs (liver, lung and kidney) by leukemic cells that were cytoplasmic CD3 + and MPO - (Figures S1B and S1C) . Consistent with previous reports using the retroviral model in mixed background B6 mice (Kelly et al., 2002) , we diagnosed the majority of 3aKO/FLT3-ITD and FLT3-ITD mice (90% and 78%, respectively) as having a T-cell disease, specifically precursor T-cell lymphoblastic lymphoma/leukemia (similar to human T-ALL), based on the Bethesda proposal for classification of murine lymphoid neoplasms (Morse et al., 2002) . The leukemic cells were capable of self-renewal as demonstrated by transplantation to sublethally irradiated WT recipients ( Figure S1D ). In addition, 22% of mice transplanted with FLT3-ITD cells and 5% with 3aKO/FLT3-ITD died from myeloproliferative disease and 5% of 3aKO/FLT3-ITD mice died of B-cell ALL ( Figure S1E ). Compared to the FLT3-ITD T-ALL cells, the 3aKO/FLT3-ITD T-ALL cells were more proliferative and had higher rates of early apoptosis by Ki-67 and annexin V staining ( Figures 1G and 1H ). These findings indicate that loss of Dnmt3a promotes aggressive T-ALL in mice that acquire FLT3-ITD.
Dnmt3a-related lymphoid leukemia upregulates myeloid programs
To understand how loss of Dnmt3a contributes to lethal lymphoid leukemia in mice, we studied the global expression profiles of the 3aKO/FLT3-ITD and FLT3-ITD T-ALLs by RNAseq. We compared the two sets of leukemic cells (>95% GFP+ and CD4 + CD8 + ) and sorted CD4 + CD8 + wild-type thymocytes from transplanted mice as a control. 3aKO mice were healthy through the time-course of this experiment, and CD4 + CD8 + cells sorted from these mice were analyzed, but had negligible differences when compared to the WT controls (data not shown).
Comparison of 3aKO/FLT3-ITD with FLT3-ITD-only cells revealed 696 differentially expressed genes (507 upregulated and 189 downregulated in the 3aKO/FLT3-ITD group) ( Figure S2A ).
Gene ontology (GO) analysis showed that in the FLT3-ITD-only group, the upregulated genes were functionally related to the extracellular region, whereas those that were upregulated in the 3aKO/FLT3-ITD-positive mice included genes related to inflammation and immune response ( Figure 2A) . Surprisingly, using Ingenuity pathway analysis we found that myeloid gene sets were upregulated in the 3aKO/FLT3-ITD group ( Figure 2B ), while genes involved in mature Tcell function were downregulated ( Figure 2C ). Other downregulated genes include several genes that are mutated or play a role in suppression of apoptosis in hematopoietic diseases (e.g. Cd28, Rorc, Ephb6) (Maddigan et al., 2011; Rohr et al., 2016; Tian et al., 2015) . Gene set enrichment analysis revealed that upregulated genes in 3aKO/FLT3-ITD cells were enriched for immature gene sets, including hematopoietic stem cells (e.g. Gata2, H19) and mouse early thymic progenitor expression. The upregulated genes were also enriched for myeloid, AML (e.g. , Hmox1, Tbxas1) , and aging gene sets ( Figure S2B ). The enriched gene sets were highly differentially expressed in 3aKO/FLT3-ITD compared to FLT3-ITD and WT cells ( Figure 2C ). research study (Haferlach et al., 2010) . Specifically, we compared genes differentially expressed in the 3aKO/FLT3-ITD leukemia model to signatures that distinguish human disease subtypes (leukemia precursor, ALL, and AML) from all other disease patients in MILE. The mouse model profile was strongly associated with genes characterizing human AML (odds ratio 15.5, p-val = 2.23E-16) ( Figure 2D and S2C) . Interestingly, the strength of association between the model and human ALL was considerably less than expected by chance (odds ratio 0.24, pval = 1.12E-08). These data suggest that in the absence of Dnmt3a, murine lymphoid leukemic cells maintain the expression of T-cell surface markers, but activate a myeloid gene signature at the cost of mature T-cell genes, which is reminiscent of human early immature T cell leukemias that are enriched in aberrant myeloid genes (Van Vlierberghe et al., 2011) .
G0s2
The T-ALL diagnosed in 3aKO/FLT3-ITD mice is similar to early T-cell precursor T-ALL (ETP-ALL), which is associated with FLT3 and DNMT3A mutations and the expression of stem and myeloid genes (Neumann et al., 2012; Neumann et al., 2013) . The ETP classification is immunophenotypic, and requires the absence of the T-cell marker CD8 (and others) (Coustan- Smith et al., 2009; Neumann et al., 2012; Zhang et al., 2012) . T-ALL can alternatively be classified solely on the basis of gene expression profiles. In this strategy, two distinct classes of immature vs mature, cortical T-ALL with unique survival and mutation profiles are evident (Van Vlierberghe et al., 2013) . The immature T-ALL group, associated with dismal survival, is distinguished by a myeloid and stem cell gene expression signature and is enriched for DNMT3A mutations (Van Vlierberghe et al., 2013) . While having some overlap with ETP-ALL, the immature classification includes cases with a variety of surface markers, including expression of CD4 and CD8 (Coustan-Smith et al., 2009; Van Vlierberghe et al., 2013) .
Considering the surface marker profile (CD4+CD8+), and myeloid and stem cell-associated gene expression signatures in the leukemia we observe, the 3aKO/FLT3-ITD cells most closely resembles early immature T-ALL. To confirm the immature phenotype, we tested the expression of Notch pathway and early thymic progenitor-related genes by quantitative PCR and found them to be downregulated and upregulated, respectively, as is expected in early immature T-ALL ( Figure S2D ). Therefore, these data indicate that 3aKO/FLT3-ITD lymphoid leukemia is most similar to human early immature T-ALL.
Dnmt3a-loss initiates myeloid and lymphoid Flt3-ITD leukemia
The strategy described above was highly effective in generating early immature-like Tcell leukemia, which is also associated with DNMT3A and FLT3 mutations in patients. More frequently however, this combination of mutations is seen in acute myeloid leukemia (AML) (Ley et al., 2010; Neumann et al., 2012) . In an attempt to generate myeloid disease, we turned to a Figure   3A ). Consistent with previous reports, ablation of Dnmt3a alone led to a broad spectrum of hematologic diseases (Celik et al., 2014; Mayle et al., 2014) , and the Flt3-ITD KI group did not develop lethal disease after transplantation (Lee et al., 2007 ). Yet, all of the 3aKO/Flt3-ITD KI group died of acute leukemia with a median survival of 225 days, which is not significantly different than the 3aKO alone ( Figure 3B ), although the spectrum of diseases is different ( Figure   4G ), and the median survival is significantly shorter than the Flt3-ITD KI group, which all survive longer than 400 days. The 3aKO/Flt3-ITD KI mice exhibited leukocytosis and myeloproliferation ( Figure 3C and 3D), and 8/14 mice were diagnosed with AML, as indicated by myeloid cell surface markers and leukemic cell infiltration in bone marrow and spleen ( Figures 3E and S3 ) (Kogan, 2002) . Two mice exhibited mixed lineage leukemia, consisting of a blast-filled bone marrow ( Figure 3F ) that stained for either myeloid or T-cell surface markers but also had an enlarged thymus infiltrated by donor-derived T-lymphoblasts ( Figure 3G ). The remaining four mice were diagnosed with T-ALL.
To verify complete deletion of Dnmt3a in these animals, we tested a subset of AML and T-ALL samples and bone marrow and thymus tissue from mice with mixed-lineage leukemia for Dnmt3a deletion by PCR. Although ER-Cre generally recombines loxP sites with high efficiency, we noted residual floxed allele in most of the AML samples (representative samples in Figure   3H ). In contrast, Dnmt3a deletion appeared to be complete in most T-ALL samples. We were initially surprised to find both lymphoid and myeloid leukemia in the Flt3-ITD knock-in mouse model known for myeloid disease but these data suggested a correlation between Dnmt3a dosage and disease type, with a remaining allele of Dnmt3a more likely found in myeloid rather than lymphoid leukemia. As discussed above, AML patients most frequently harbor mono-allelic mutation of DNMT3A at R882, which is thought to retain some DNMT3A activity, while T-ALL patients much more commonly harbor biallelic DNMT3A mutations, consistent with more complete loss-of-function. analyzed died from AML with a median survival of 270 days ( Figure 4A ). These 3aHet/Flt3-ITD KI mice developed myelocytosis in the peripheral blood ( Figure 4B and C) with increased monocytes and neutrophils ( Figure 4D ). Histological examination revealed leukemic blast cell infiltration in the bone marrow ( Figure 4E ), peripheral blood ( Figure S4A ), and extramedullary organs (liver, lung, kidney) ( Figure S4B ). The blasts expressed myeloid cell surface markers (Mac-1 + Gr-1 + c-Kit + ) ( Figures 4F and S4C ). The disease was recapitulated when transplanted to secondary recipients ( Figure S4D) Figure   S5 ).
Heterozygous
Of the cohort of mice transplanted with 3aHet/Flt3-ITD KI cells, 90% developed AML ( Figure 4G ), in striking contrast to the 3aKO/Flt3-ITD KI cohort, of which only 57% developed AML with the rest exhibiting T-ALL or mixed lineage leukemia, and the 3aKO cohort, which we have previously reported develop a variety of malignancies (Mayle et al., 2014) . Together, these observations indicate a relationship between Dnmt3a-dosage and the type of disease development.
Dnmt3a-associated leukemia arises from HSCs
In AML patients, DNMT3A mutations have been found in HSCs, acting as a preleukemic lesion (Corces-Zimmerman et al., 2014; Ding et al., 2012; Shlush et al., 2014) .
However, whether this DNMT3A mutant cell, or other downstream populations, can serve as the leukemia stem cell (LSC) is not known. Indeed, in some leukemias, LSCs arise from committed progenitors that acquire the ability to self-renew such as MLL-AF9 leukemia (Krivtsov et al., 2006) , whereas in others, it arises from an HSC such as in c-Cbl-related leukemia (Rathinam et al., 2010 Figure 5A ), and the T-ALL we saw previously was recapitulated ( Figure 5B ). These data indicate that this Dnmt3a-deficient lymphoid leukemia originated from a transformed HSC rather than downstream progenitor cells. To determine whether each population could propagate the disease, we also sorted various GFP+ populations from the mice after T-ALL development, and transplanted them. In this cohort, T-ALL was recapitulated in most mice ( Figure 5C and 5D),
suggesting that more committed populations propagated the disease, despite only the HSCs being able to initiate the disease.
In the Flt3-ITD KI AML model, we tested for leukemia initiation by inducing Dnmt3a deletion by tamoxifen injection and transplanting purified cells one week later. In this short time frame, Dnmt3a-deleted HSCs would likely have only limited contribution to downstream populations. Thus, any contribution of sorted progenitors or differentiated cells to AML development would indicate that Dnmt3a-deletion may exert its effects downstream of the HSC.
We sorted LT-HSC, ST-HSC, MPP, CMP, GMP, and CLP and transplanted them into lethally irradiated WT recipients ( Figure 5E ). Only the LT-HSC population showed long-term engraftment and development of the AML phenotype by peripheral blood analysis, whereas other populations showed only transient blood contribution, indicating more limited self-renewal (Figures 5F and 5G) . These data establish that in Dnmt3a-related AML, the undifferentiated HSCs initiate the leukemia, in contrast to models of leukemia such as MLL-AF9 in which granulocyte/macrophage progenitors give rise to the disease (Krivtsov et al., 2006) .
Loss of DNMT3A drives enhancer hypomethylation
Recent reports have shown a correlation between DNMT3A mut and specific hypomethylation patterns in CN-AML (cytogenetically normal AML) patients (Qu et al., 2014; Russler-Germain et al., 2014 ). Because we were utilizing a genetically defined model, we could identify specific patterns of DNA methylation changes resulting from loss of DNMT3A in our mouse models. We first sought to assess these changes in the T-ALL model. We generated genome-wide DNA methylation maps of 3aKO/FLT3-ITD and FLT3-ITD leukemic cells, and CD4 + CD8 + WT thymocytes by whole genome bisulfite sequencing (WGBS; coverage 8-10x; 7.2 million CpGs with at least 5x coverage across all samples). The overall methylation differences between sample groups were minor, but all comparisons revealed loci with increased and loci with decreased DNA methylation, similar to what has been observed in human hematologic malignancies (Figueroa et al., 2013; Figueroa et al., 2010 ), yet the greatest magnitude of hypomethylation occurred in samples lacking Dnmt3a ( Figure 6A ).
We next focused on specific regions such as CpG islands, shores, and regulatory elements such as promoters and enhancers (Hon et al., 2013; Lara-Astiaso et al., 2014) . In 3aKO/FLT3-ITD-derived cells, nearly all of these features exhibited marked hypomethylation, with the greatest magnitude of change found in enhancer sites defined in hematopoietic tissues (bone marrow, spleen, thymus) and at the edges of large undermethylated regions (canyons) (Jeong et al., 2014) ; >15% of enhancers and canyons were hypomethylated, a proportion ~ 5-fold greater than observed by chance ( Figure 6B and Figure S6A ). In FLT3-ITD-only leukemic cells, by contrast, hypermethylation of enhancers and canyon edges was much more prominent ( Figure 6B ).
To confirm that 3aKO hypomethylated enhancer sites were regulatory elements relevant to hematopoiesis, we examined them for enrichment of hematopoiesis-related transcription factor-binding sites. We compared our findings to a database of 315 mouse chromatin immunoprecipitation (ChIP)-seq transcription factor studies involving over 400,000 regions (Ruau et al., 2013) . The comparison revealed overrepresentation of more than 80 transcription factors at hypomethylated enhancer sites, including master regulators that determine cell fate during stem, myeloid and lymphoid cell differentiation such as Fli1, Gfi1b, and Pu.1 ( Figure   S6B ). Many of the transcription factors identified have also been implicated in hematopoietic diseases, including Fli1, Lmo2, and Runx1 in T-ALL Mok et al., 2014; Smeets et al., 2013; Smith et al., 2014) , and Pu.1 and Runx1 in AML (Cancer Genome Atlas Research, 2013; Gerloff et al., 2015) . These findings suggest that Dnmt3a loss results in the demethylation of previously methylated, functionally relevant enhancer regions during leukemogenesis, thus potentially increasing accessibility of these regions to relevant transcription factors.
To further confirm that loss of DNMT3A unveils enhancer sites, we generated maps of putative enhancers ) based on H3K27ac and H3K4me1 histone peaks in leukemic FLT3-ITD and 3aKO/FLT3-ITD cells by ChIP-seq and DNAse1 hotspots from mouse ENCODE database (Consortium et al., 2012) . We identified 13,705 regions co-occupied by H3K27ac and H3K4me1 in 3aKO/FLT3-ITD and assessed differential enrichment of H3K27ac and H3K4me1 at these regions. At these co-occupied regions, the interquartile-range distributions of both marks' signals showed greater intensity in 3aKO/FLT3-ITD cells ( Figure   S6C ). We observed differential enrichment of one or both marks in 3aKO/FTL3-ITD cells at 29.4% (4031 / 13705) of regions tested ( Figure S6D ). We also observed an overwhelming trend towards increased occupancy of both H3K4me1 and H3K27ac, implying that many regions in 3aKO/FLT3-ITD have acquired the chromatin marks de novo relative to FLT3-ITD alone ( Figure   6C ). We asked whether these regions with changes in H3K4me1 or H3K27ac also differed in DNA methylation. In regions with differential enrichment of both H3K4me1 and H3K27ac, the proportion of hypomethylated CpG sites was significantly greater in 3aKO/FLT3-ITD than FLT3-ITD (odds ratio 3.16, CI 2.89 -3.44, P-val < 2.2e-16, Fisher's exact test) ( Figure 6D ). The increase in enrichment of H3K27ac and H3K4me1 peaks at hypomethylated regions in the leukemic cells that lack DNMT3A strongly suggests that DNMT3A regulates active enhancers.
Given the observations that DNA methylation of enhancers was reduced with loss of Dnmt3a, we considered whether exogenous expression of Dnmt3a would restore methylation levels at those sites. Leukemic cells derived from 3aKO/FLT3-ITD secondary transplants were transduced with a retrovirus expressing Dnmt3a along with a GFP marker (MSCV-Dnmt3a-IRES-GFP) or GFP alone (MSCV-GFP) and were transplanted into sublethally irradiated tertiary recipients. Methylome maps of recipient bone marrow cells using RRBS (average of 19 million mapped reads per sample) revealed increased average DNA methylation in tumors with enforced Dnmt3a expression ( Figure 6E and 6F). Furthermore, enhancers, CGI shores, and canyon edges all showed significant hypermethylation ( Figure S6E ). These data support our observations that DNMT3A is particularly active at enhancers. Expression of Dnmt3a did not affect the survival of the mice, consistent with Dnmt3a being more important for leukemic initiation than maintenance (despite an estimated 4-fold higher Dnmt3a expression than that in GFP-transduced samples (data not shown)).
While the 3aKO/FLT3-ITD model showed clear methylation losses, we considered whether the heterozygous Dnmt3a AML model would exhibit similar effects on DNA methylation.
We examined the methylome of three 3aHet/Flt3-ITD KI AML samples compared to three sorted stem and progenitor cells (KSL) samples from transplanted Flt3-ITD KI mice by reduced representation bisulfite sequencing (RRBS) (total of 16-37 million reads with at least 13 million aligned reads). Overall mean CpG methylation was not different between the two genotypes ( Figure S6F ). However, of interrogated CpGs, there were more hypomethylated 1-kb regions than hypermethylated regions ( Figure 6G ). Further analysis of genomic regions revealed more frequent hypomethylation at enhancer regions defined as hematopoietic (bone marrow, spleen, and thymus) and more frequent hypermethylation of enhancers in lineages such as testes and cerebellum ( Figure 6H ). Therefore, in the absence of one allele of Dnmt3a, loss of methylation was the most frequent event in the murine model of AML.
To more directly compare methylation changes in the 3aHet/Flt3-ITD KI AML model with the 3aKO/FLT3-ITD T-ALL model, we repeated our methylation analysis on the T-ALL samples using RRBS. Even though RRBS is more biased toward CpG islands, which frequently show hypermethylation, we confirmed enhancers and canyons were dramatically undermethylated in the T-ALL leukemic cells ( Figure S6G ). Therefore, in both models, RRBS analysis demonstrated that canyon edges were subject to the most frequent methylation changes, with CGIs and promoters having the least frequent methylation changes ( Figure 6H ). Although we observe more extreme hypomethylation in the T-ALL model (possibly due to the lower dosage of DNMT3A), the shared hypomethylation of enhancers and frequent altered methylation at canyon edges strongly suggest that these regions in particular are regulated by DNMT3A.
Re-expression of DNMT3A inhibits transcription factor binding at enhancers
Having observed significant hypomethylation particularly at enhancer sites in the absence of DNMT3A, we considered whether this had functional consequences on transcription factor binding. We hypothesized that remethylation of enhancer binding sites in the presence of enforced DNMT3A expression would result in lower occupancy of some transcription factors.
To test this, we utilized the T-ALL model because of the homogeneity of this leukemia and the complete absence of Dnmt3a expression. In addition to being implicated in T-cell development and T-ALL (Smeets et al., 2013; Smeets et al., 2014) , FLI1 exhibited robust gene expression across conditions, was not differentially expressed, and the FLI1 consensus binding motif was enriched in hypomethylated enhancer sequences (P = 3.59e-15, Bonferroni correction), so we decided to test the effect of re-methylation on FLI1 binding. We performed ChIP-seq for FLI1 in were significantly enriched for hematopoietic enhancer regions that are also hypomethylated in the absence of DNMT3A (odds ratio 2.35 P = 5.26e-06, Fisher's test). Whether FLI1 has a role in this particular leukemia is not clear, but it serves to support the concept that DNA methylation changes can affect transcription factor occupancy at enhancer sites ( Figure 7D ).
Mutant DNMT3A/FLT3 AML patients also exhibit enhancer DNA hypomethylation
Given the findings of DNA methylation changes at enhancer regions when Dnmt3a is lost and ectopically expressed, we considered whether patients with DNMT3A mut also exhibited DNA methylation loss at hematopoietic enhancer regions. For our analysis, we selected from the TCGA cohort patients with the DNMT3A R882 mutation as this group is of sufficient size to allow statistical analysis, and the R882 mutation has been functionally characterized as a dominant negative (Kim et al., 2013; Russler-Germain et al., 2014) . Patients with non-R882 mutations were excluded from our analysis due to their uncharacterized nature and small numbers. Leukemic cells with the R882 mutation are thought to retain around 20% of wild-type activity, so we cannot exclude some effects peculiar to this mutant that would be distinct from the Dnmt3aKO mouse situation.
We mined the TCGA AML patient dataset to compare the DNA methylation maps of AML patients with co-mutations of DNMT3A R882 and FLT3 to those with either mutation alone or to patients of normal karyotype (WT NK AML) lacking either mutation ( Figure 8A ) (Cancer Genome Atlas Research, 2013) . To better control for other mutations that may have epigenetic effects, patients with mutations in IDH1, IDH2, TET1, or TET2 were excluded. All patients harbor cytoplasmic NPM1. We observed a dramatic increase in CpG hypomethylation (n = 35,436 sites) in patients with R882 and FLT3 mutations compared to FLT3 alone ( Figure 8B ), a unique result (among the group comparisons) in that it completely spanned the inter-quartile range of changes at sites of variable methylation in the four patient groups. The hypomethylated sites were significantly enriched for enhancers and to a lesser extent, CpG island shores ( Figure   8C ). While limited hypomethylation (n = 3437 sites) was observed in patients with FLT3 and R882 co-mutation compared to R882 alone ( Figure 8B ), the methylation states we observed in enhancer regions at sites of variable methylation clearly discriminated the two patient groups from one another, though to a lesser extent than either from the WT or FLT3 alone groups ( Figure 8D ). We mapped the enhancers to gene regulatory domains and assessed what biological functions most distinguished those hypomethylated in R882 + FLT3 mutant patients relative to the larger population of enhancers. They were enriched for sequence-specific (including enhancer) binding transcriptional regulators, corepressors, genes involved in cell fate specification, targets of PTEN, p53, PRC2, as well as genes with conserved homeobox sites ( Figure S7A ). To investigate the transcriptional profile of genes with hypomethylated enhancers,
we generated linear models of RNA-seq counts for 69 AML patients in the TCGA dataset, contrasting the DNMT3A mutation status among patients harboring FLT3 mutations. Ingenuity knowledge-based functional enrichment analysis of differentially expressed, hypomethylatedenhancer associated genes showed over-representation in functions supporting hematopoietic progenitor cells (including quantity, proliferation, and maturation) as well as disease states, including myeloproliferative disorders and AML ( Figure 8E ). Applying a more unbiased approach, GSEA, we observed a strong, negative correlation with targets of MYC and E2F, as well as genes involved in the G2/M cell cycle checkpoint ( Figure S7B ). We also observed overexpression of homeobox genes, including the HOXB cluster (members 2 -5) consistent with other reports (Yan et al., 2011) . These data indicate that in AML patients with mutated FLT3, the loss of enhancer methylation observed with mutation of DNMT3A may contribute to deregulation of transcriptional programs key to cell identity and normal hematopoietic function, thus promoting leukemogenesis.
DISCUSSION
Here, we have generated a mouse model of human DNMT3A mut leukemia and show that deletion of Dnmt3a cooperates with the FLT3-ITD mutation to initiate both myeloid and lymphoid leukemias, establishing a powerful model to investigate the mechanisms of Dnmt3a-associated transformation. Because the promoter used to drive FLT3-ITD expression in mice has been reported to affect disease development (Lee et al., 2007) , we utilized both a retroviral transduction model, which leads primarily to lymphoid disease (Kelly et al., 2002) , and a knockin model, which leads to myeloproliferative disease (Lee et al., 2007) .
We have previously reported that loss of Dnmt3a predisposes transplanted mice to a variety of hematologic diseases such as B-and T-ALL, MDS, AML, CMML and primary myelofibrosis, (Mayle et al., 2014) . Here, we combined loss of Dnmt3a with FLT3-ITD retroviral overexpression, which led to rapid T-cell leukemia that resembled early immature lymphoid leukemia. The Flt3-ITD knock-in combined with Dnmt3a loss led primarily to myeloid leukemia that resembled the M4/M5 subtypes of AML, which are highly associated with DNMT3A mutations (Yan et al., 2011) . Thus, combining FLT3-ITD with loss of Dnmt3a drove development of specific diseases. This suggests that loss of Dnmt3a establishes a cellular milieu that is permissive for transformation down either the myeloid or lymphoid lineage, and that the secondary hits play a key role in disease specification and latency.
Importantly, the Dnmt3a/Flt3-ITD knock-in model also generated a number of lymphoid leukemias that were more prevalent with complete absence of Dnmt3a, whereas heterozygous Dnmt3a loss almost exclusively led to myeloid leukemia. These data establish that Dnmt3a dosage influences the lineage outcome of Flt3-ITD leukemia. This observation is consistent with the observation that the mutational spectrum of DNMT3A is distinct among patients with lymphoid vs. myeloid leukemias (reviewed in (Yang et al., 2015) ). Yet, the mechanism behind the differential dependence on DNMT3A is not clear. During the natural evolution of leukemia, patients will initially have a single mutant allele, and probably sustain that state for some time.
Thus, we can conjecture that a patient acquiring a dominant-negative R882 mutation would have ~20% of WT DNMT3A activity, while those with a nonsense mutation might have 50% activity remaining. Both these levels will be haploinsufficient, and may influence the differentiation of HSCs, such that myeloid differentiation may be favored in the R882 case, where lymphoid differentiation is favored when DNMT3A is present at a higher level. This suggests that a greater amount of DNMT3A maybe required for normal lymphoid differentiation.
In T-ALL, the second DNMT3A lesion is probably acquired later and likely leads to rapid leukemia development down the lymphoid pathway.
Our data also reinforce the concept that DNMT3A functions primarily at the stem cell level. Both the myeloid and lymphoid leukemias are initiated by HSCs transformed with FLT3-ITD. Our findings indicate that Dnmt3a loss in stem cells likely primes the pre-leukemic clone for a secondary oncogenic hit at the stem cell level. These data are consistent with the highly specific effect that Dnmt3a loss has on expansion of the stem cell compartment (Challen et al., 2012 ). In addition, the inability to slow the leukemia by re-expression of DNMT3A suggests that DNMT3A loss is important for leukemia initiation, but probably less so for maintenance. This association with initiation and stem cells is also seen in patients, as DNMT3A mut can be found in multiple lineages with DNMT3A mut AML, indicating it first emerges in HSC-or progenitorgenerated clones (Corces-Zimmerman et al., 2014; Jan et al., 2012; Shlush et al., 2014) .
Furthermore, in patients with AML, DNMT3A mut are thought to be the initiating event, as they are almost always found at the highest variant allele frequencies . Together, these data lead to a model in which an HSC acquires a DNMT3A mutation, which expands and remains as a reservoir for clonal expansion until a new genetic lesion, such as FLT3-ITD, is acquired and leads to full leukemic transformation. leukemia (Groschel et al., 2014) . Furthermore, during HSC differentiation, changes in DNA methylation are mapped to regulatory elements and transcription factor binding sites (CabezasWallscheid et al., 2014) , supporting our findings that DNMT3A regulates distal regulatory elements by DNA methylation in leukemogenesis. Dnmt3a loss in non-leukemic HSCs can also induce hypomethylation at distal regulatory elements (Jeong et al., 2014) , indicating that our observations are Dnmt3a-specific. Our discoveries imply that during leukemogenesis, DNMT3A
Methylation profiling of
acts as a tumor suppressor, guarding stem-cell regulatory regions through methylation at enhancers (Hnisz et al., 2013; Hon et al., 2013; Ziller et al., 2013) .
Overall, these experiments show that Dnmt3a loss drives leukemogenesis in multiple lineages, recapitulating DNMT3A mut AML and T-ALL in a Dnmt3a-dosage dependent manner.
These mouse models serves as a valuable tools to study and develop therapeutic targets for DNMT3A-related leukemia. allele (Challen et al., 2012) on the C57BL/6 background were used to harvest bone marrow cells, which were then transplanted by retro-orbital injection into lethally irradiated (9.5 Gy)
CD45.1 syngeneic mice. Tamoxifen treatment was performed with 5 intraperitoneal injections of 100μg each, Mx1-cre mice were induced with 6 intraperitoneal injections of pIpC (Sigma, 300 μg per mouse in PBS) on alternating days.
Mouse Phenotype analysis
Tissues-femur, tibiae, iliac crests, spleen, and thymus-were harvested and made into singlecell suspension by manual trituration. Peripheral blood was obtained retro-orbitally and cells were stained with antibodies at 1:100 dilution at 4°C, analyzed on a LSR II flow cytometer (BD Biosciences), or sorted with a BD FACSAria II cell sorter (BD Biosciences) (Mayle et al., 2013) .
For histologic studies, fresh tissues were made into touch preps or fixed and mounted for H&E staining.
Cell sorting
Bone marrow cells were isolated as described above. Cells were enriched for CD117 by magnetic enrichment (Miltenyi Biotec). Enriched cells were stained with the stem and progenitor antibodies described the Supplemental Experimental Procedures and sorted on a four-laser FACSAria (BD Biosciences). Sorted cells were transplanted as described above.
RNA/DNA Sequencing
RNA and DNA were isolated with AllPrep DNA/RNA mini kit (Qiagen). We made 100 bp pairedend WGBS and RNA-seq (Illumina TruSeq DNA or RNA Sample Preparation Kit) and RRBS libraries (Boyle et al., 2012 ) from 2 to 3 biological replicates. Briefly, 1ug of genomic DNA was fragmented and made into libraries, undergoing two rounds of bisulfite conversion (Qiagen EpiTect Bisulfite Kit) (Jeong et al., 2014) . DNA libraries were sent to BCM Genomic and RNA
Profiling Core for quality control and sequenced on Illumina HiSeq sequencing systems.
Demultiplexing analysis was run allowing one mismatch in the index read on undetermined reads. Adapter and base quality trimming was performed with Trimgalore for all raw data files using a Phred score threshold 20. RNA and DNA sequencing analysis are described in supplemental experimental procedures. The WGBS, RRBS, and RNA-seq data will be deposited prior to publication in Gene Expression Omnibus of the National Center for Biotechnical Information and accession numbers will be provided. Hypomethylated enhancers covered at least 3 CpGs and their mean methylation difference between R883+FLT3 and FLT3 was < -0.15. Gene and CpG island annotations were from the Illumina annotation file. Promoter probes includes the four categories TSS1500, TSS200, 5'UTR and first exon. Enhancer probes were assigned by overlap of H3K27ac or H3K4me1 peaks outside of Refseq promoter regions. H3K27ac peaks and H3K4me1 peaks were called by MACS2 (Zhang et al., 2008) with CD34+ primary cells (GSM772885 and GSM706845).
TCGA DNA methylation analysis
Statistics
All values are means ± s.e.m. Comparisons between groups were made with ANOVA, the logrank test, or Student's t-test, using Graphpad Prism 5.0b. 
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. All bars denote mean ± s.e.m values *P < 0.05 and ** P < 0.01 and *** P < 0.001 by one-way ANOVA. See also Figure S1 . mice. See also Figure S4 . 
